Therapy Area topics
Cardiovascular
Bioresorbable scaffolds flounder as Reva heads to bankruptcy
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
Bayer and Merck & Co need Vitality data to breathe life into vericiguat, while Akero awaits its first big test with the Nash project AKR-001.
Astra and Acasti throw the Amarin bulls more fodder
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
Central Nervous System
Novo Nordisk’s quiet entry into the year of Alzheimer’s
An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
Nektar’s clearing event clears away $500m
As a US adcom gives the strongest possible indication that oxycodegol won’t be approved, Nektar’s valuation loses 11%.
Diabetes
As Nash shifts again, the focus remains on Genfit’s big readout
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Digital Health
Livongo enters the medtech float hall of fame
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Fewer than 200 medtech VC rounds closed in 2018
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Oncology
The joker in Exelixis and Bristol’s kidney cancer pack
The first-line Checkmate-9ER study will read out soon, and could show whether two arch rivals can together defeat a common enemy.
Respiratory
Clinical win gives Verona a kiss of life
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
Upcoming events – TG's long-awaited outcome and Insmed's mid-stage lung data
After making investors wait more than a year, TG Therapeutics is gearing up to release results of its lead leukaemia combo, while Insmed hopes to succeed in a very tricky…
The other shoe drops for Gossamer’s GB001
Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.
Various
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
Bayer and Merck & Co need Vitality data to breathe life into vericiguat, while Akero awaits its first big test with the Nash project AKR-001.
Upcoming events – Pfizer's abrocitinib and Myovant's relugolix
Pfizer's abrocitinib heads against Dupixent in atopic dermatitis, while Myovant hopes to raise its Spirits.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.